Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Lexalytics Announces New Partnerships to Improve Insights, Efficiencies and Patient Outcomes in AI for Medical Affairs Programs

True North Solutions and Glasshouse Health Partner with Lexalytics to Help Pharmaceutical Companies and Other Healthcare Providers in North America and Europe

Lexalytics, the leader in “words-first” machine learning and artificial intelligence, announced today it is partnering with True North Solutions and Glasshouse Health to help Medical Affairs teams better apply the latest in artificial intelligence and natural language processing (NLP) technologies and approaches to improve insights, efficiencies and patient outcomes. True North and Glasshouse bring decades of domain expertise in the pharmaceutical and healthcare industries in the North American and European markets, respectively, and will work with Lexalytics to help customers understand how applied AI and machine learning (ML) solve real-world business problems.

Off-the-shelf technology solutions tend to be poorly suited to address the unique needs of Medical Affairs in areas such as insight generation, automation, compliance review, educational gap assessment, congress and publication planning, and digital innovation. Lexalytics, True North and Glasshouse have partnered to help Med Affairs functions better understand how to apply AI and NLP to address all of the noted issues, as well as the many other responsibilities of a Medical Affairs department.

Recommended AI News: MemVerge and Analytical BioSciences Accelerate Cancer and COVID-19 Research With Big Memory

“Over the past few years, we’ve been applying machine learning to many of the facets of pharmaceutical Medical Affairs and commercial functions to improve efficiencies, insights and patient outcomes, and our customers have seen tremendous success through those efforts,” said Jeff Catlin, CEO of Lexalytics. “By partnering with the skilled teams at True North and Glasshouse, we hope to reach more Medical Affairs departments across North America and Europe to quicken adoption and improve outcomes of AI and NLP projects in the space.”

Lexalytics has built AI and NLP solutions for some of the world’s most prominent pharmaceutical and biotech companies, including Avenir, AlternativesPharma, Biogen, Genentech, Sage Therapeutics and more. Some of the recent and ongoing projects that Lexalytics has undertaken in Medical Affairs with its partners include:

Related Posts
1 of 33,631

● Medical Information Question-Answering System — By combining machine learning with keyword search, Lexalytics built a system for a leading Japanese biopharmaceutical company that reduces average call times without sacrificing the quality of responses. The system is essentially a search interface that uses an AI and NLP model underpinning it that processes a particular question against FAQs and other literature to deliver the best answers at the top. The system makes agents faster and more accurate, which reduces the need to elevate requests to a medical professional (MP), significantly reducing costs.

● Content Aggregation — Lexalytics has designed and built disease- and condition-specific taxonomies that can apply across all of the content in a given organization. Typically this involves combining existing tags with new tags suggested by Lexalytics’ models into a single taxonomy for use throughout the organization. Being able to make an apples-to-apples comparison of Congress, field insights, research content and everything else means that teams can perform detailed data analytics across all content for use in marketing, compliance and other areas on which Medical Affairs concentrates.

● Field Insights & Engagement Tracking — Lexalytics has built a system combining NLP tools with custom taxonomies and advanced visualizations to help Medical Affairs teams gauge, in one place, what transpires during high-cost, high-value Medical Science Liaison (MSL) customer interactions. The system objectively tracks key themes, sentiment, and perceptions recorded in brief, free-text interactions by MSLs following their discussions with healthcare providers (HCP), significantly increasing the MSL value and ensuring HCP feedback is better incorporated into medical strategies.

Recommended AI News: InMotion Hosting Announces the Acquisition of RamNode

“We’ve just begun to scratch the surface of what is possible using AI in Medical Affairs to improve operations and outcomes, and pharmaceutical companies and other healthcare providers are eager to learn about the possibilities,” said Colin Baughman, founder and managing partner, True North Solutions. “I’ve consulted with Lexalytics on several past and current projects and am excited to expand our partnership to continue to drive innovation.”

“I’ve spent more than two decades driving strategy, product planning, development, patient program development and more with Medical Affairs teams, and I know the critical role technology plays in ensuring success,” said Paul Riley, Medical Affairs director, Glasshouse Health. “Thanks to developments in AI and NLP, Medical Affairs teams can contribute to the business in ways they have never been able to before, as demonstrated by the projects delivered by Lexalytics.”

Recommended AI News: Qualys and HCL Technologies Expand Partnership to Secure the Digital Transformation of Enterprises

1 Comment
  1. BENTYL injection 20 mg/2 mL (10 mg/mL) 4 CONTRAINDICATIONS BENTYL is contraindicated in infants less than 6 months of
    age [see Use in Specific Populations (8.4)], nursing mothers [see Use in Specific Populations (8.3)], and in patients with

Leave A Reply

Your email address will not be published.